Colon cancer edrecolomab

Punt CJ, Nagy A, Douillard JY, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer A randomised study. Lancet 2002 360 671-677. 

Edrecolomab is a murine monoclonal antibody to the cell-surface glycoprotein 17-lA, which is expressed on epithelial tissues and on various carcinomas. This 17-lA antigen is also known as EGP-2, Ep-CAM, C017-1A, or GA733-2. Preliminary data suggested that it might be of use in the adjuvant treatment of patients with resected stage III colon cancer. 

Edler L, Hochhaus A, Queisser W. Adjuvant therapy with edrecolomab versus observation in stage n colon cancer a multicenter randomized phase III study. Onkologie 2005 28 347-50. 

Fields ALA, Keller A, Schwartzberg L, Bernard S, Kardinal K, Cohen A, Schulz J, Eisenberg P, Forster J, Wissel P. Adjuvant therapy with the monoclonal antibody edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 2009 27(12) 1941-7. 

In the initial clinical study, which focused on patients with minimal residual disease because of the presumption that overt metastatic disease might overwhelm the capacity of the immime system, 189 patients with stage III colon or rectal cancer were randomized to edrecolomab or no treatment [217 ]. On the strength of the results the drug was approved by the regulatory... 

---